INBX Filings — Inhibrx Biosciences, Inc. - FilingSpy
INBX
Inhibrx Biosciences, Inc.
A clinical-stage biopharmaceutical company engineering biologic therapies for cancer. Its lead candidate, ozekibart, cut the risk of disease progression or death in a late-stage trial for chondrosarcoma, a rare bone cancer, and it is also studying INBRX-106 with the immunotherapy Keytruda. The name blends "inhibit" and "Rx" (prescription), and the company took its present form in 2024 when Sanofi bought one of its programs, spinning out the rest.
Ozekibart BLA is under FDA review, but Q2 cash fell to $133.3M as the operating loss widened and pre-commercial spending began.
The ozekibart BLA for chondrosarcoma is now under FDA review, but the company is spending to prepare for a launch it cannot guarantee. fell to zero and the net loss widened to $36.6 million, as R&D costs rose 7% and pre-commercialization expenses pushed G&A higher. Cash declined to $133.3 million, and the company warns that observations could derail the approval it is betting on.
Key takeaways
fell to zero from $1.3 million a year ago, as the Scithera License Agreement completed.
The net loss widened to $36.6 million from $28.7 million in Q2 2025, driven by a 7% increase in R&D expense to $23.9 million and higher G&A costs tied to pre-commercialization activities for ozekibart.
G&A expense rose as the company added $1.6 million in pre-commercialization costs to prepare for a potential ozekibart launch in chondrosarcoma, even though the drug has not yet been approved.
Section summaries
Management's Discussion and Analysis
Net loss widened to $36.7M in Q2 FY2026 as R&D and pre-commercialization costs rose, offset by lower six-month R&D spend.
⌄
Q2 fell to $0 from $1.3M a year ago due to the completion of the Scithera License Agreement.
Q2 R&D expense rose 7% to $23.9M, driven by higher contract manufacturing and clinical trial costs for ozekibart and INBRX-106.
nearly doubled to $5.7 million from $2.9 million a year ago, following the $75 million debt amendment in March 2026 that increased the outstanding loan balance to $176.3 million.
Cash and equivalents fell 28.5% to $133.3 million, with an operating cash outflow of $29.9 million in the quarter; management states this is sufficient to fund operations for at least the next 12 months.
The company disclosed that observations were issued to the company and its clinical investigators in connection with the ozekibart BLA, which could delay approval or trigger a from the FDA.
What changed
The ozekibart BLA was submitted to the FDA in April 2026, meeting the timeline flagged in the FY 2025 10-K, but the filing now reveals that observations were issued, a risk not previously disclosed.
The ozekibart monetization process, a prominent risk factor in the Q3 and FY 2025 filings, was not discussed in this Q2 2026 report.
Quarterly operating cash outflow was $29.9 million, consistent with the ~$30 million level flagged as the burn rate to watch in Q2 2025, but the cash balance has fallen to $133.3 million from $186.6 million a year ago.
Initial Phase 2 data for INBRX-106 in head and neck cancer, previously expected in Q4 2025 and then Q2 2026, was not mentioned in this filing.
The I-Mab Biopharma trade secrets lawsuit, which concluded in January 2025, no longer appears as a risk factor or legal proceeding.
What to watch
Whether the FDA accepts the ozekibart BLA for review or issues a refuse-to-file or , and the resolution of the observations disclosed in this filing.
Quarterly operating cash outflow against the $133.3 million cash balance and $176.3 million in debt, to assess whether the runway holds beyond the 12 months management projects.
Any update on the ozekibart monetization process, which was absent from this filing after being a prominent risk factor in prior periods.
FDA meetings in the second half of 2026 on accelerated approval pathways for ozekibart in fourth-line colorectal cancer and Ewing sarcoma, as flagged in the Q1 2026 filing.
Six-month R&D expense declined 17% to $49.1M, primarily due to the wind-down of the ozekibart chondrosarcoma trial and lower manufacturing activity.
G&A expense increased in both periods, with $1.6M in higher pre-commercialization costs for a potential ozekibart launch in chondrosarcoma.
nearly doubled in Q2 to $5.7M following a $75M debt amendment in March 2026, while interest income fell on lower cash balances.
Cash and equivalents stood at $133.3M as of June 30, 2026, and management expects this to fund operations for at least the next 12 months.
Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required under this item.
⌄
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required under this item.
We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs,…
⌄
We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.
The company has no approved products and faces material risk that its lead candidate ozekibart may not gain FDA approval or be successfully commercialized.
⌄
The company depends entirely on two clinical-stage candidates, ozekibart and INBRX-106, with no products on the market and no guarantee of regulatory approval.
FDA review of the ozekibart for chondrosarcoma is ongoing, but observations issued to the company and clinical investigators could delay approval or trigger a .
A prior partial on the ozekibart ChonDRAgon trial followed a fatal hepatotoxicity event; although lifted, similar safety issues could halt or delay trials again.
Clinical development is expensive and uncertain: trials may be suspended or terminated by regulators or IRBs, and reliance on CROs and sites limits the company’s control over trial conduct.
Even if ozekibart is approved, the company has no commercial experience and may fail to build adequate sales, marketing, or distribution capabilities, threatening and profitability.